PL4408840T3 - Kwasy benzoimidazolokarboksylowe jako agoniści glp-1r - Google Patents

Kwasy benzoimidazolokarboksylowe jako agoniści glp-1r

Info

Publication number
PL4408840T3
PL4408840T3 PL22793036.9T PL22793036T PL4408840T3 PL 4408840 T3 PL4408840 T3 PL 4408840T3 PL 22793036 T PL22793036 T PL 22793036T PL 4408840 T3 PL4408840 T3 PL 4408840T3
Authority
PL
Poland
Prior art keywords
glp
agonists
carboxylic acids
benzimidazole carboxylic
benzimidazole
Prior art date
Application number
PL22793036.9T
Other languages
English (en)
Inventor
Corey REEVES
F. Anthony Romero
Christopher T. Jones
Martijn Fenaux
Original Assignee
Terns Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals, Inc. filed Critical Terns Pharmaceuticals, Inc.
Publication of PL4408840T3 publication Critical patent/PL4408840T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL22793036.9T 2021-09-27 2022-09-27 Kwasy benzoimidazolokarboksylowe jako agoniści glp-1r PL4408840T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163261717P 2021-09-27 2021-09-27
PCT/US2022/044915 WO2023049518A1 (en) 2021-09-27 2022-09-27 Benzimidazole carboxylic acids as glp-1r agonists

Publications (1)

Publication Number Publication Date
PL4408840T3 true PL4408840T3 (pl) 2025-12-22

Family

ID=83899713

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22793036.9T PL4408840T3 (pl) 2021-09-27 2022-09-27 Kwasy benzoimidazolokarboksylowe jako agoniści glp-1r

Country Status (25)

Country Link
US (7) US20230150998A1 (pl)
EP (2) EP4537899A3 (pl)
JP (1) JP2024534621A (pl)
KR (1) KR20240068737A (pl)
CN (1) CN118251391A (pl)
AU (1) AU2022349020A1 (pl)
CA (1) CA3233201A1 (pl)
CL (1) CL2024000861A1 (pl)
CO (1) CO2024005060A2 (pl)
DK (1) DK4408840T3 (pl)
ES (1) ES3049198T3 (pl)
FI (1) FI4408840T3 (pl)
HR (1) HRP20251161T1 (pl)
HU (1) HUE073500T2 (pl)
IL (1) IL311667A (pl)
LT (1) LT4408840T (pl)
MX (1) MX2024003872A (pl)
PE (1) PE20241130A1 (pl)
PL (1) PL4408840T3 (pl)
PT (1) PT4408840T (pl)
RS (1) RS67271B1 (pl)
SI (1) SI4408840T1 (pl)
SM (1) SMT202500374T1 (pl)
TW (1) TW202322806A (pl)
WO (1) WO2023049518A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4408840T3 (pl) 2021-09-27 2025-12-22 Terns Pharmaceuticals, Inc. Kwasy benzoimidazolokarboksylowe jako agoniści glp-1r
IL312364A (en) 2021-10-25 2024-06-01 Luehr Gary W Compounds as GLP-1R agonists
IL315151A (en) 2022-02-23 2024-10-01 Terns Pharmaceuticals Inc Compounds as glp-1r agonists
WO2024051700A1 (zh) * 2022-09-05 2024-03-14 德睿智药(苏州)新药研发有限公司 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物
WO2024206647A1 (en) * 2023-03-29 2024-10-03 Terns Pharmaceuticals, Inc. Polymorphic forms and salts of a glp-1r agonist
TW202506131A (zh) 2023-04-07 2025-02-16 美商拓臻製藥公司 ＧＬＰ－１Ｒ及ＴＨＲβ激動劑之組合以及其使用方法
WO2024212742A1 (zh) * 2023-04-10 2024-10-17 上海研健新药研发有限公司 一种glp-1r激动剂，其制备方法和应用
WO2025057134A2 (en) 2023-09-14 2025-03-20 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305623D0 (en) 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
DE69413523T2 (de) 1993-03-18 1999-05-12 Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire Benzimidazole derivate
GB9305641D0 (en) 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US6960589B2 (en) 2001-03-09 2005-11-01 Abbott Laboratories Benzimidazoles that are useful in treating sexual dysfunction
BR0206161A (pt) 2001-10-19 2005-02-01 Ortho Mcneil Pharm Inc 2-fenil benzimidazóis e imidazo-[4,5]-piridinas como inibidores de cds1/chk2 e adjuvantes para quimioterapia ou terapia por radiação no tratamento de câncer
US20040127504A1 (en) 2002-09-06 2004-07-01 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
WO2004099192A2 (en) 2003-04-30 2004-11-18 The Institutes Of Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
BRPI0710083A2 (pt) 2006-03-31 2011-08-02 Janssen Pharmaceutica Nv entidade quìmica benzoimidazol-2-il pirimidina e pirazina, composição farmacêutica e uso destas
WO2008012623A1 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
NZ595819A (en) 2009-04-02 2013-02-22 Merck Serono Sa DIHYDROOROTATE DEHYDROGENASE INHIBITORS; benzimidazole-4-carboxylic acid
US8580807B2 (en) 2009-04-03 2013-11-12 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders
AU2011253057B2 (en) 2010-05-13 2014-11-20 Amgen Inc. Nitrogen heterocyclic compounds useful as PDE10 inhibitors
HRP20251088T1 (hr) 2012-07-01 2025-11-07 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp‑1
WO2015166398A1 (en) 2014-04-30 2015-11-05 Aurigene Discovery Technologies Limited 3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
MX387259B (es) 2016-12-16 2025-03-18 Pfizer Agonistas receptores de glp-1 y usos de los mismos
JP7461104B2 (ja) 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
JP7053900B2 (ja) 2018-06-15 2022-04-12 ファイザー・インク Ｇｌｐ－１受容体アゴニストおよびその使用
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
SG11202101503RA (en) 2018-08-31 2021-03-30 Pfizer Combinations for treatment of nash/nafld and related diseases
MA54555A (fr) 2018-11-22 2021-09-29 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations
WO2020117987A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions and methods for the treatment of liver disorders
CU20210083A7 (es) 2019-04-12 2022-05-11 Qilu Regor Therapeutics Inc Agonistas de glp-1r
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2021018023A1 (zh) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
CN114630823B (zh) * 2019-10-25 2025-01-28 吉利德科学公司 Glp-1r调节化合物
KR20210059584A (ko) 2019-11-15 2021-05-25 일동제약(주) Glp-1 수용체 작용제 및 이의 용도
EP4058445B1 (en) 2019-11-15 2025-03-26 Ildong Pharmaceutical Co., Ltd. Glp-1 receptor agonist and use thereof
CN114761395B (zh) * 2019-12-02 2024-11-15 现代药品株式会社 Glp-1受体激动剂
US20230045419A1 (en) 2019-12-10 2023-02-09 Pfizer Inc. Solid Forms of 2-((4-((S)-2-(5-Chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt
EP4523751A3 (en) 2020-01-29 2025-05-28 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2021155841A1 (en) 2020-02-07 2021-08-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4103563A4 (en) 2020-02-13 2024-03-06 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
CA3171173A1 (en) 2020-03-18 2021-09-23 Young Kwan Kim Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
CN113493447B (zh) 2020-04-03 2024-06-11 轩竹(北京)医药科技有限公司 Glp-1受体激动剂
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
CN115667250A (zh) 2020-04-29 2023-01-31 加舒布鲁姆生物公司 杂环glp-1激动剂
PL4157832T3 (pl) 2020-05-27 2024-12-16 Qilu Regor Therapeutics Inc. Sól i postacie krystaliczne agonistów GLP-1R oraz ich zastosowania
CN111548311B (zh) 2020-06-04 2021-04-23 山西医科大学 一种小分子glp-1r激动剂及其应用
ES3049538T3 (en) 2020-06-04 2025-12-17 Hangzhou Sciwind Biosciences Co Ltd Five-membered heteroaromatic imidazole compound and use thereof
WO2021249492A1 (zh) 2020-06-10 2021-12-16 南京明德新药研发有限公司 甲基取代的苯并二噁唑类化合物及其应用
TW202214610A (zh) 2020-06-19 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 ６－側氧－３，６－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
WO2021259309A1 (zh) 2020-06-24 2021-12-30 广州市恒诺康医药科技有限公司 Glp-1受体激动剂及其药物组合物和用途
EP4182020A1 (en) 2020-07-20 2023-05-24 Eccogene (Shanghai) Co., Ltd. Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same
WO2022031994A1 (en) 2020-08-06 2022-02-10 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
CA3192601A1 (en) 2020-08-21 2022-02-24 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
JP2023538949A (ja) 2020-08-28 2023-09-12 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
CN119930603A (zh) 2020-09-01 2025-05-06 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN116615430A (zh) 2020-09-07 2023-08-18 加舒布鲁姆生物公司 杂环glp-1激动剂
CN116368140A (zh) 2020-09-10 2023-06-30 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2022068772A1 (zh) 2020-09-29 2022-04-07 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
US20250263402A1 (en) 2020-10-12 2025-08-21 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Benzimidazolone glp-1 receptor agonist and use thereof
EP4229050A4 (en) 2020-10-13 2024-12-11 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2022078380A1 (en) 2020-10-13 2022-04-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP7769695B2 (ja) 2020-10-14 2025-11-13 キル・レガー・セラピューティクス・インコーポレーテッド Ｇｌｐ－１ｒアゴニストの結晶形態およびその使用
US11851419B2 (en) 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
WO2022111624A1 (zh) 2020-11-27 2022-06-02 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
CN114591308B (zh) 2020-12-03 2024-03-08 苏州闻泰医药科技有限公司 一类glp-1r受体激动剂化合物及其用途
MX2023007569A (es) 2020-12-25 2023-09-21 Xizang Haisco Pharmaceutical Co Ltd Derivado de anillo de cinco miembros y uso medico de este.
CR20230330A (es) 2021-01-28 2023-11-15 Carmot Therapeutics Inc Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2022192430A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4317142A4 (en) 2021-03-22 2025-02-26 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. THIOPHENE-TYPE GLP-1 RECEPTOR AGONIST AND ITS USE
WO2022199661A1 (en) 2021-03-24 2022-09-29 Eccogene (Shanghai) Co., Ltd. Phenyl- [1, 3] dioxolo [4, 5-c] pyridinyl-phenyl-, phenyl- [1, 3] dioxolo [4, 5-c] pyridinyl-heteroaryl-, or phenyl- [1, 3] dioxolo [4, 5-c] pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo [d] imidazole-carboxylic acid derivatives and methods of using same
JP7772778B2 (ja) 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
ES2925124B2 (es) 2021-03-29 2024-04-08 Fundacion Univ San Antonio Tratamiento de la obesidad
JP2024514259A (ja) 2021-04-08 2024-03-29 エルジー・ケム・リミテッド Ｇｌｐ－１受容体作動薬、それを含む薬学的組成物、およびその製造方法
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
DK4271672T3 (da) 2021-04-21 2026-02-16 Gilead Sciences Inc Carboxy-benzimidazol glp-1r-modulerende forbindelser
CN117177970A (zh) 2021-04-30 2023-12-05 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用
BR112023022836A2 (pt) 2021-05-03 2024-01-16 Carmot Therapeutics Inc Agonistas de receptores de glp-1 benzimidazoíla, composições farmacêuticas que compreendem os mesmos e métodos para seu uso
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
KR20240021212A (ko) 2021-06-10 2024-02-16 안타그 테라퓨틱스 에이피에스 비만 및 비만-관련 장애의 치료
EP4361145A4 (en) 2021-06-24 2025-05-21 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1 receptor agonist and composition and use thereof
US20240382471A1 (en) 2021-07-21 2024-11-21 Hepagene Therapeutics (HK) Limited Glucagon-like peptide-1 receptor modulators and uses thereof
CN113480534B (zh) 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
AU2022321506A1 (en) 2021-08-04 2024-02-01 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Cycloalkene derivative regulator, preparation method therefor, and application thereof
WO2023016546A1 (en) 2021-08-12 2023-02-16 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
KR20240099142A (ko) 2021-08-27 2024-06-28 버사니스 바이오, 인크. 병용 요법
EP4353717A4 (en) 2021-08-30 2025-01-15 Mindrank AI Ltd. Novel aryl ether substituted heterocyclic compound as glp1r agonist
CN117940422A (zh) 2021-08-31 2024-04-26 辉瑞大药厂 2-[(4-{6-[(4-氰基-2-氟芐基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-羧酸，1,3-二羟基-2-(羟甲基)丙-2-胺盐的固体形式
AU2022344074A1 (en) 2021-09-08 2024-02-29 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
PL4408840T3 (pl) 2021-09-27 2025-12-22 Terns Pharmaceuticals, Inc. Kwasy benzoimidazolokarboksylowe jako agoniści glp-1r
US20250236627A1 (en) 2021-10-05 2025-07-24 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
US20240417393A1 (en) 2021-10-05 2024-12-19 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
TWI843243B (zh) 2021-10-22 2024-05-21 大陸商盛世泰科生物醫藥技術（蘇州）股份有限公司 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途
IL312364A (en) 2021-10-25 2024-06-01 Luehr Gary W Compounds as GLP-1R agonists
WO2023106310A1 (ja) 2021-12-07 2023-06-15 塩野義製薬株式会社 Ｇｌｐ－１受容体アゴニスト活性を有する芳香族複素環誘導体
CN114280573B (zh) 2021-12-09 2025-09-26 上海禾赛科技有限公司 激光雷达及其测量目标反射率的方法和系统
WO2023111145A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US20250066338A1 (en) 2021-12-16 2025-02-27 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023124824A1 (zh) 2021-12-29 2023-07-06 海思科医药集团股份有限公司 一种glp-1激动剂的盐及其晶型和在医药上的应用
CN119343339A (zh) 2022-01-24 2025-01-21 加舒布鲁姆生物公司 杂环glp-1激动剂
JP2025506474A (ja) 2022-02-09 2025-03-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
CN119343343A (zh) 2022-02-09 2025-01-21 加舒布鲁姆生物公司 杂环glp-1激动剂
TW202342014A (zh) 2022-02-10 2023-11-01 瑞士商諾華公司 １，３－苯并二氧戊環衍生物
IL315151A (en) 2022-02-23 2024-10-01 Terns Pharmaceuticals Inc Compounds as glp-1r agonists
CA3253533A1 (en) 2022-02-28 2023-08-31 Ascletis Bioscience Co., Ltd. GLP-1R MODULATOR COMPOUNDS
JP2025509281A (ja) 2022-03-09 2025-04-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
EP4496797A1 (en) 2022-03-21 2025-01-29 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
JP2025513071A (ja) 2022-04-14 2025-04-22 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
CN114716423A (zh) 2022-05-20 2022-07-08 中国科学院上海药物研究所 5,6-二氢-1,2,4-三嗪类化合物及其作为glp-1受体激动剂的药学用途
CA3249144A1 (en) 2022-05-20 2025-06-17 Chengdu Di'ao Jiuhong Pharmaceutical Factory BENZIMIDAZOLE OR AZABENZIMIDAZOLE COMPOUND, ITS PREPARATION PROCESS AND ITS USE
CN120379988A (zh) 2022-08-24 2025-07-25 广州市联瑞制药有限公司 苯并双环类化合物及其制备方法和应用
WO2024046342A1 (zh) 2022-08-30 2024-03-07 广州市联瑞制药有限公司 苯并双环类化合物及其制备方法和应用
WO2024051700A1 (zh) 2022-09-05 2024-03-14 德睿智药(苏州)新药研发有限公司 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物
JPWO2024063140A1 (pl) 2022-09-22 2024-03-28
JPWO2024063143A1 (pl) 2022-09-22 2024-03-28
JP2025537254A (ja) 2022-11-11 2025-11-14 イーライ リリー アンド カンパニー グルカゴン様ペプチド１受容体アゴニスト
IL320810A (en) 2022-11-16 2025-07-01 Lilly Co Eli Glucagon-like peptide 1 receptor agonists
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024149080A1 (zh) 2023-01-13 2024-07-18 中国科学院上海药物研究所 用作glp-1受体激动剂的4-烷氧基苯并咪唑-6-羧酸衍生物
WO2024206647A1 (en) 2023-03-29 2024-10-03 Terns Pharmaceuticals, Inc. Polymorphic forms and salts of a glp-1r agonist
TW202444350A (zh) 2023-03-29 2024-11-16 美商拓臻製藥公司 作為ｇｌｐ—１ｒ激動劑之化合物

Also Published As

Publication number Publication date
AU2022349020A1 (en) 2024-05-09
US20250145615A1 (en) 2025-05-08
US12378238B2 (en) 2025-08-05
RS67271B1 (sr) 2025-10-31
IL311667A (en) 2024-05-01
PE20241130A1 (es) 2024-05-24
EP4537899A2 (en) 2025-04-16
DK4408840T3 (da) 2025-10-27
CL2024000861A1 (es) 2024-10-04
US20250145613A1 (en) 2025-05-08
JP2024534621A (ja) 2024-09-20
US20250145616A1 (en) 2025-05-08
WO2023049518A1 (en) 2023-03-30
US20230150998A1 (en) 2023-05-18
US20250145614A1 (en) 2025-05-08
US12522596B2 (en) 2026-01-13
EP4408840B1 (en) 2025-08-13
US12378237B2 (en) 2025-08-05
SMT202500374T1 (it) 2025-11-10
FI4408840T3 (fi) 2025-11-04
EP4537899A3 (en) 2025-06-25
US20250145612A1 (en) 2025-05-08
US20250282772A1 (en) 2025-09-11
ES3049198T3 (en) 2025-12-15
LT4408840T (lt) 2025-10-10
CO2024005060A2 (es) 2024-05-30
EP4408840A1 (en) 2024-08-07
TW202322806A (zh) 2023-06-16
US12378239B2 (en) 2025-08-05
CN118251391A (zh) 2024-06-25
US12378236B2 (en) 2025-08-05
SI4408840T1 (sl) 2025-12-31
MX2024003872A (es) 2024-04-19
KR20240068737A (ko) 2024-05-17
CA3233201A1 (en) 2023-03-30
HUE073500T2 (hu) 2026-01-28
HRP20251161T1 (hr) 2025-11-21
PT4408840T (pt) 2025-10-07

Similar Documents

Publication Publication Date Title
IL311667A (en) Benzimidazole carboxylic acids as GLP-1R agonists
MY195385A (en) Glp-1 Receptor Agonists And Uses Thereof
ZA202007304B (en) Glp-1 receptor agonists and uses thereof
GEAP202215517A (en) Glp-1 receptor agonists and uses thereof
ZA201903665B (en) 3-substituted propionic acids as alpha v integrin inhibitors
ZA201100048B (en) Method for the production of free carboxylic acids
LT4192831T (lt) Heterocikliniai glp#1 agonistai
HUE068174T2 (hu) Heterociklusos GLP-1 agonisták
PL4143183T3 (pl) Heterocykliczni agoniści glp-1
AP2016009615A0 (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
MY205872A (en) Pharmaceutical compositions comprising omega-3 fatty acids
ZA200810796B (en) Method for the continuous production of unsaturated carboxylic acid anhydrides
BRPI0719784A2 (pt) Processo para preparação de aidas terciárias de ácidos alquilfenilcarboxílicos
IL232979A0 (en) Herbicidal preparation containing certain carboxylic acids of pyridine and acetic acid (4,2-di-chlorophenoxy)
PL3747859T3 (pl) Ciągły sposób wytwarzania pochodnych nasyconych kwasów karboksylowych
SG11201907296UA (en) Novel ester compounds, method for the production thereof and use thereof
ZA201200413B (en) Process for the preparation of pyrazole carboxylic acid amides
ZA201808449B (en) Process for pd-catalyzed hydroxycarbonylation of diisobutene: ratio of 3,5,5-trimethylhexanoic acid / h2o
GB201919268D0 (en) Methods and compositions comprising carboxylic acids
IL217134A (en) Process for making (2, 4-dimethylbiphenyl-3-yl) acetic acids, esters and intermediates
ZA201808494B (en) Process for pd-catalyzed hydroxycarbonylation of diisobutene: acetic acid / diisobutene ratio
MX2018011529A (es) Procesos para la preparacion de acidos heteroaril carboxilicos.
EP3904334A4 (en) COMPOSITION FOR THE PREPARATION OF AN N-VINYL CARBONIC AMIDE
MX2018015526A (es) Proceso para la conversion directa de diisobuteno a un acido carboxilico.
MX2018015533A (es) Proceso para la conversion directa de los alquenos a acidos carboxilicos.